Results 131 to 140 of about 5,630,058 (301)

The Retina as a Biomarker for Vascular and Neurodegenerative Brain Diseases [PDF]

open access: yes, 2018
Over the years, the research field investigating the eye-brain connection has increased steeply, and researchers have begun to recognize the potential to use retinal structures as biomarkers for brain diseases.
Mutlu, U. (Ünal), Mutlu, Ünal
core   +1 more source

MARK4 enhances stress granule formation under oxidative stress and increases tau accumulation

open access: yesFEBS Open Bio, EarlyView.
MARK4 (red dots) localizes to stress granules (orange dots) and promotes their formation under oxidative stress by modulating TIA1 (blue dots). MARK4 and TIA1 synergistically increase tau (purple) accumulation, and the reduction of the TIA1 ortholog suppresses neurodegeneration in a fly model.
Sho Nakajima   +8 more
wiley   +1 more source

Beta1 subunits enable fentanyl‐induced BK channel activation and opioid regulation of cerebral artery diameter

open access: yesFEBS Open Bio, EarlyView.
During the current opioid crisis, the majority of overdose deaths are attributed to ultra‐potent synthetic opioids, such as fentanyl. While fentanyl exerts its action via opioid receptors, we propose that potassium channels in the brain blood vessels may also sense fentanyl.
Shiwani Thapa   +4 more
wiley   +1 more source

Gut–brain axis in health and brain disease

open access: yesChinese Medical Journal
Abstract The gut–brain axis is a complex, bidirectional network of communication systems that integrates neural, endocrine, and immune pathways, as well as metabolic processes, to regulate homeostasis and maintain physiological and cognitive equilibrium. Central to this axis is the gut microbiota, which exerts a
Olasunkanmi, Oluwatayo Israel   +2 more
openaire   +3 more sources

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

open access: yesFEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao   +23 more
wiley   +1 more source

GBS‐MeDIP: A method for the simultaneous identification of genetic and epigenetic variants in tumors

open access: yesFEBS Open Bio, EarlyView.
GBS‐MeDIP combines DNA sequencing with enrichment of methylated DNA to profile genetic and epigenetic variation in the same reduced genomic fraction. Applied to gastric cancer and parathyroid tumors, it identifies sequence variants, copy number changes, and differentially methylated regions together, helping distinguish true epigenetic changes from ...
Fábio Pértille   +6 more
wiley   +1 more source

Febrilna stanja i encefalopatski sindrom [PDF]

open access: yesVojnosanitetski Pregled, 2002
Raičević Ranko   +8 more
doaj   +1 more source

National Clinical Programme for Rare Diseases Workshop on Clinical Research in Rare Diseases

open access: yes, 2018
The National Clinical Programme was established in December 2013. It is an initiative of the HSE, in partnership with the Royal College of Physicians. A key objective of the Clinical Programme for Rare Diseases is to improve access for rare diseases ...
National Clinical Programme for Rare Diseases
core  

Acute Kidney Injury After Mechanical Thrombectomy for Stroke in Patients With Pre‐Existing Renal Impairment

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Acute kidney injury (AKI) is a common but often underrecognized complication in ischemic stroke patients undergoing mechanical thrombectomy, particularly among those with pre‐existing renal impairment. This study evaluated the incidence, risk factors, and clinical impact of AKI in this high‐risk population.
Michał Borończyk   +10 more
wiley   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy